Inotuzumab ozogamicin is an investigational antibody-drug conjugate (ADC), which features a monoclonal antibody (mAb) targeting CD22,9 cell surface antigen expressed on about 90% of B-cell malignancies,10 linked to
The trial, which will also include study sites in Europe and Australia, is designed to identify whether the company’s pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses ifosfamide chemotherapy)
MERS was initially found in Saudi Arabia in 2012. It is an illness caused by a coronavirus known as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Hemispherx said
The randomised, double blind, multicentre trials will evaluate the efficacy and safety of intravenous iclaprim versus intravenous vancomycin in the treatment of acute bacterial skin and skin structure
Trabodenoson, which is the company’s lead clinical candidate, is being investigated to reduce intraocular pressure. About 335 patients diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)
The CRL states that additional clinical information is required to support the company’s new drug application (NDA). It includes clinical trial data from ongoing or completed studies and
The company plans to start a commercial launch of the drug in major European countries in early next year. Earlier this year, the European Medicines Agency’s Committee for
The funding will be used for the study to discover antibodies against Ebola virus and identify how they prevent Ebola virus infection, allowing to develop Ebola therapeutics and
The company said that the results of the trial were not statistically significant, in which the primary endpoint of change from baseline in the six-minute walk test (6MWT)
The deal is expected to generate more than $200m for Emisphere. Under the deal, Emisphere will receive a $5m upfront licensing fee from Novo Nordisk, and is eligible
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.